Clinical Trials Logo

Cardiogenic Shock clinical trials

View clinical trials related to Cardiogenic Shock.

Filter by:
  • Withdrawn  
  • Page 1

NCT ID: NCT05661773 Withdrawn - Cardiogenic Shock Clinical Trials

Digital Ischemia Reduction in Critically Ill Patients

DIR
Start date: November 2023
Phase: N/A
Study type: Interventional

Patients requiring high dose pressors (minimum 2) who are unlikely to be weaned off them over 1 day will be identified. Patients will have the device applied to one hand while expectant medical management will continue to the contralateral hand.

NCT ID: NCT04876040 Withdrawn - Cardiogenic Shock Clinical Trials

Incorporating Supersaturated Oxygen in Shock

ISO-SHOCK
Start date: December 17, 2021
Phase: N/A
Study type: Interventional

A multi-center, prospective randomized (1:1) pilot and feasibility study to evaluate the safety and feasibility of supersaturated oxygen (SSO2) therapy delivered for 60 minutes selectively into the culprit coronary artery of patients presenting with ST elevation myocardial infarction and cardiogenic shock (STEMI-CS) treated using a shock protocol.

NCT ID: NCT04206865 Withdrawn - Cardiogenic Shock Clinical Trials

Comparison of ARNI to Alternate Oral Vasodilator Therapies in Patients With Low Cardiac Output

PARAVLO-HF
Start date: November 25, 2019
Phase: Phase 4
Study type: Interventional

This is a prospective, randomized, non-blinded, single-center efficacy study of acutely decompensated heart failure patients with reduced ejection fraction (HFrEF), low cardiac index (<2.2) as determined by pulmonary artery catheter (PAC) who have been hemodynamically stabilized and ready for transition to oral vasodilator therapy at the discretion of the clinician. The investigators would like to accomplish the following objectives with this study: 1. Establish the superiority of an upfront initiation strategy for sacubitril-valsartan at maintaining patients on ARNI therapy at one-month follow-up compared to usual care. 2. Establish the safety of initiating sacubitril-valsartan in an intensive care setting 3. Characterize the hemodynamic effect of sacubitril-valsartan on patients with low cardiac output 4. Expand the population of hospitalized patients that can be initiated on ARNIs and thus facilitate prior to hospital discharge patients who are on optimal goal-directed medical therapy (GDMT) for heart failure